Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.63 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789884 | 0.86 | KCNH2 (0.66) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL21197944 | 0.86 | KCNH2 (0.57) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3359340 | 0.85 | KCNH2 (0.62) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3355445 | 0.85 | KCNH2 (0.62) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3359338 | 0.85 | KCNH2 (0.62) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL923075 | 0.84 | KCNH2 (0.47) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL4133825 | 0.84 | KCNH2 (0.59) | KCNH2 | |
| SCHEMBL922035 | 0.84 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL921593 | 0.84 | CNR2 (0.46) | KCNH2 | |
| SCHEMBL706100 | 0.84 | KCNH2 (0.45) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052597-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| EP-3746438-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | Cadila Healthcare Limited (IN) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019145919-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2019-08-01 | — | — | WO | disclosed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | KCNH2 2142/4885SCN7A 1260/4885SCN5A 632/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885SCN7A 4165/4885SCN5A 2187/4885 |
| US-20210052597-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | ABCB11, DHPS, MRPL21 | KCNH2 1415/4885SCN7A 2656/4885SCN5A 1368/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885SCN7A 4165/4885SCN5A 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.